Trial of vibegron yields favorable results for patients with OAB
October 16th 2021"We believed that the drug would work as well in OAB wet as it did in OAB dry, so we're pleased to see that it was statistically significantly better than placebo at the 12-week point for looking at response to both metrics in both group," says David Staskin, MD.
White paper addresses ethical considerations for older patients with incontinence
October 15th 2021"As a committee, we felt that there was a need to put together a document to help field some of the ethical considerations that we run into in clinical care but have very little guidance on," says Anne M. Suskind, MD, MS, FACS, FPMRS.
Disparities in ED diagnosis and referral across clinics who serve varying demographics
October 5th 2021To examine the disparities of ED diagnosis and referral, Denise Asafu-Adjei, MD, MPH, and a team of investigators conducted a study involving 2 outpatient urology settings who serve communities with varying demographics.
Understanding patterns in prostate genomic testing using SEER and GPS assay
October 4th 2021In a recent study presented at the 2021 AUA Annual Meeting, Scarlett Gomez, MPH, PhD, and co-authors investigated the determinants of selecting active surveillance/watchful waiting as a treatment path for patients with localized, low-risk prostate cancer.
Phase 2b data point to safety, efficacy of focal therapy in intermediate-risk prostate cancer
October 1st 2021In a study presented at the 2021 AUA annual meeting, Behfar Ehdaie, MD, MPH, and colleagues assessed the efficacy of focal therapy in treating patients with grade group 2 or 3 prostate cancers.
Noninvasive miR Sentinel PCC4 Test accurately identifies prostate cancer
September 30th 2021In a recent study presented at the 2021 AUA Annual Meeting, Laurence Klotz, MD, FRCSC, and a team of investigators determined the accuracy of the new miR Sentinel PCC4 Test, a urinalysis of low- to high-grade prostate cancer in men.
Study finds commercial prices for prostatectomies are not associated with treatment patterns
September 27th 2021"What will probably be surprising to the reader is that patients managed in markets with higher average prices for prostatectomy were not more likely to undergo treatment," says Lillian Y. Lai, MD.
Long-term follow-up of OLYMPUS study shows promising results for patients with UTUC
September 27th 2021In a study presented at the 2021 AUA Annual Meeting, Karim Chamie, MD, and coauthors further examine the long-term results of UGN-101 for patients with LG UTUC given the favorable outcomes of the initial OLYMPUS trial.
Aquablation demonstrates success in large prostates
September 25th 2021In a recent study presented at the 2021 AUA Annual Meeting, Naeem Bhojani, MD, FRCSC, David-Dan Nguyen, and co-authors reported the favorable 3-year results of ongoing Aquablation research specifically involving patients with large prostates.